These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 17953423)
21. The updated Swiss guidelines 2016 for the treatment and follow-up of cutaneous melanoma. Dummer R; Siano M; Hunger RE; Lindenblatt N; Braun R; Michielin O; Mihic-Probst D; von Moos R; Najafi Y; Guckenberger M; Arnold A Swiss Med Wkly; 2016; 146():w14279. PubMed ID: 26901103 [TBL] [Abstract][Full Text] [Related]
22. Therapy of melanoma with allogeneic melanoma lysates alone or with interferon-alfa. Mitchell MS; Darrah D; Stevenson L Cancer Invest; 2002; 20(5-6):759-68. PubMed ID: 12197233 [No Abstract] [Full Text] [Related]
23. Adjuvant therapy of high-risk malignant melanoma patients with gamma interferon. Landthaler M; Braun-Falco O J Am Acad Dermatol; 1989 Apr; 20(4):687-8. PubMed ID: 2497156 [No Abstract] [Full Text] [Related]
24. [High-dose interferon-alpha and adjuvant treatment of melanoma with poor prognosis: requiem for a drug marketing license?]. Saiag P Ann Dermatol Venereol; 1999 Mar; 126(3):211-3. PubMed ID: 10394432 [No Abstract] [Full Text] [Related]
25. The role of adjuvant therapy in melanoma management. Barth A; Morton DL Cancer; 1995 Jan; 75(2 Suppl):726-34. PubMed ID: 7805001 [TBL] [Abstract][Full Text] [Related]
26. [Modern tumor therapy as seen in melanoma]. Dummer R; Nestle FO; Burg G Praxis (Bern 1994); 1996 Dec; 85(50):1609-14. PubMed ID: 8999490 [TBL] [Abstract][Full Text] [Related]
27. Therapy for metastatic melanoma: an overview and update. Boyle GM Expert Rev Anticancer Ther; 2011 May; 11(5):725-37. PubMed ID: 21554048 [TBL] [Abstract][Full Text] [Related]
33. Adjuvant use of interferon alpha 2b is not justified in patients with stage IIb/III melanoma. Bajetta E Nat Clin Pract Oncol; 2008 Jan; 5(1):4-5. PubMed ID: 18043604 [No Abstract] [Full Text] [Related]
34. Melanoma. Benson C; Gore ME Cancer Chemother Biol Response Modif; 2001; 19():629-38. PubMed ID: 11686036 [No Abstract] [Full Text] [Related]
35. Adjuvant interferon in melanoma - a resurrection? Middleton MR; Thatcher N Br J Cancer; 2001 May; 84(9):1141-2. PubMed ID: 11336461 [No Abstract] [Full Text] [Related]
36. [Guidelines for stage I to III melanoma]. Guillot B; Dalac S; Denis M; Dupuy A; Emile JF; De La Fouchardiere A; Hindie E; Jouary T; Lassau N; Mirabel X; Piperno Neumann S; De Raucourt S; Vanwijck R Bull Cancer; 2016 Sep; 103(9):743-52. PubMed ID: 27456259 [No Abstract] [Full Text] [Related]
37. Current and planned multicenter trials for patients with primary or metastatic melanoma. Sondak VK; Han D; Deneve J; Kudchadkar R J Surg Oncol; 2011 Sep; 104(4):430-7. PubMed ID: 21858839 [TBL] [Abstract][Full Text] [Related]
38. [Surgical and adjuvant drug therapy in head and neck cutaneous melanoma]. Hauschild A; Lischner S; Christophers E Laryngorhinootologie; 2000 Jul; 79(7):428-33. PubMed ID: 11005097 [TBL] [Abstract][Full Text] [Related]
39. A retrospective cost-effectiveness analysis of interferon as adjuvant therapy in high-risk resected cutaneous melanoma. Messori A; Becagli P; Trippoli S; Tendi E Eur J Cancer; 1997 Aug; 33(9):1373-9. PubMed ID: 9337677 [TBL] [Abstract][Full Text] [Related]
40. Molecular targeted therapy in melanoma: a way to reverse resistance to conventional drugs. Maira F; Catania A; Candido S; Russo AE; McCubrey JA; Libra M; Malaponte G; Fenga C Curr Drug Deliv; 2012 Jan; 9(1):17-29. PubMed ID: 22023213 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]